Chapter 1
CHAPTER 2 1. “Management of Substance Abuse”, World Health Organization, https://www.who.int/substance_abuse/facts/cannabis/en/ 2. Hui-Lin Li, “An Archaeological and Historical Account of Cannabis in China”, Economic Botany, Vol. 28, No. 4 (Oct. - Dec., 1974), pp. 437-448 3. Ren, M et al, “The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs”, Science Advances, 12 Jun 2019: Vol. 5, no. 6, eaaw1391 DOI: 10.1126/sciadv.aaw1391 4. Xiaozhai Lu and Robert C. Clarke, “The cultivation and use of hemp (Cannabis sativa L.) in ancient China” http://www.druglibrary.org/olsen/hemp/iha/iha02111.html 5. Ethan B. Russo, “History of Cannabis and Its Preparations in Saga, Science, and Sobriquet”, Chemistry and Biodiversity, 21 August 2007, https://doi.org/10.1002/cbdv.200790144 6. G.N. Chaturvedi, et Al, “CLINICAL SURVEY OF CANNABIS USERS IN VARANASI“, Ancient Science of Life, 1991 Jan-Mar; 10(3): 194–198, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3331287/. 7. Godlaski, T, “Shiva, Lord of Bhang”, Substance Use and Misuse, Volume 47, 2012 - Issue 10, https://www.tandfonline.com/doi/abs/10.3109/10826084.2012.684308?src=recsy s&journalCode=isum20 8. S L Acharya et Al, “Cannabis, Lord Shiva and Holy Men: Cannabis Use Among Sadhus in Nepal”, J Psychiatric Association of Nepal, Vol .3, No.2, 2014, https://www.researchgate.net/publication/277644738_Cannabis_Lord_Shiva_and _Holy_Men_Cannabis_Use_Among_Sadhus_in_Nepal 9. Acharya, Rabinarayan & Dhiman, Kartar & Ranade, Anagha & Naik, Raghavendra & Prajapati, Shashikant & Lale, sanjeev. (2015). Vijaya (Cannabis sativa Linn. ) and its therapeutic importance in Ayurveda; a review. Journal of Drug research in Ayurvedic sciences. 1. 1-12. 10. Roger Pertree, “Handbook of Cannabis”, OUP Oxford, 21 Aug, https://books.google.co.uk/books?id=uu5wBAAAQBAJ&dq=von+Esenbeck+and+ Ebermaier+1830&source=gbs_navlinks_s 2014 11. E Russo, “Cannabis and cannabis extracts: Greater than the sum of their parts?”, CANNABIS THERAPEUTICS IN HIV/AIDS, January 2001, DOI: 10.1300/J175v01n03_08 12. E Russo, Cannabis Treatments in Obstetrics and Gynecology: A Historical Review, Journal of Cannabis Therapeutics 2(3-4):5-35 · June 2002 13. (Osler and Mccrae 1915) 14. E Russo, The pharmacological history of cannabis, Handbook of Cannabis, OUP Oxford, 21 Aug 15. M Lee, “Smoke Signals: A Social History of Marijuana - Medical, Recreational and Scientific”, Scribner Book Company; 14 Aug. 2012 16. D Bewley-Taylor, M Jelsma, T Blickman, “The Rise and Decline of Cannabis Prohibition”, https://www.tni.org/en/publication/the-rise-and-decline-of-cannabis- prohibition 17. Reefer Madness, https://www.youtube.com/watch?v=zhQlcMHhF3w 18. “Single Convention On Narcotic Drugs”, United Nations, 1961 https://www.unodc.org/pdf/convention_1961_en.pdf 19. J Mills, “The IHO as Actor: The case of cannabis and the Single Convention on Narcotic Drugs 1961”, Hygiea Int. 2016 Dec 7; 13(1): 95–115. 20. D Bewley-Taylor, M Jelsma, “Regime change: Re-visiting the 1961 Single Convention on Narcotic Drugs” , International Journal of Drug Policy, 17 August 2011 21. Robert Clarke, Mark Merlin, “Cannabis: Evolution and Ethnobotany”, Univ of California Press, 2013 22. J Boutain, “On the Origin of Hops (Humulus, Cannabaceae)”, [Honolulu] : [University of Hawaii at Manoa], [May 2014] 23. Legal Medical Marijuana States and DC, https://medicalmarijuana.procon.org/legal-medical-marijuana-states-and-dc/
Chapter 3
1. M ElSohly,D Slade, “Chemical constituents of marijuana: The complex mixture of natural cannabinoids”, Life Sciences, Volume 78, Issue 5, 22 December 2005, Pages 539-548 2. P Morales, D Hurst, P Reggio, “Molecular Targets of the Phytocannabinoids-A Complex Picture”, Prog Chem Org Nat Prod. 2017; 103: 103–131 3. A Chicca et al, “Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high”, Science Advances 24 Oct 2018: Vol. 4, no. 10 4. Y Asakawa, “Liverworts-Potential Source of Medicinal Compounds”, Current pharmaceutical design · February 2008 5. S Raduner et Al, “Alkylamides from Echinacea Are a New Class of Cannabinomimetics CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND - INDEPENDENT IMMUNOMODULATORY EFFECTS”, The Journal of Biological Chemistry, May 19, 2006 6. Masao Toyota et Al, “New Bibenzyl Cannabinoid from the New Zealand Liverwort Radula marginata”, Chemical and Pharmaceutical Bulletin, 2002, https://www.jstage.jst.go.jp/article/cpb/50/10/50_10_1390/_article/-char/ja/ 7. Lumír Ondřej Hanus, “Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids”, Medicinal Research Reviews, 05 September 2008 8. F Cullman, “Prenylated Bibenzyls from the Liverwort Radula laxiramea”, A Journal of Biosciences, Published Online: 2014-06-02 | DOI: https://doi.org/10.1515/znc-1999-3-401 9. JuditHohmann et Al, “Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors”, Phytochemistry, Volume 72, Issues 14–15, October 2011, Pages 1848-1853 10. JÜRG GERTSCH, “New Natural Noncannabinoid Ligands for Cannabinoid Type- 2 (CB2) Receptors”, Journal of Receptors and Signal Transduction, Volume 26, 2006 - Issue 5-6 11. Belén Palomares et al, Tetrahydrocannabinolic Acid a (THCA-A) Reduces Adiposity and Prevents Metabolic Disease Caused by Diet-Induced Obesity, Biochemical Pharmacology doi: 10.1016/j.bcp.2019.113693 12. Pagano E, et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsiesfrom UC pediatric patients. Pharmacol Res. 2019 Nov;149:104464. doi:10.1016/j.phrs.2019.104464. Epub 2019 Sep 22. PubMed PMID: 31553934.
13. Joana Gonçalves et Al, “Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination”, Medicines (Basel). 2019 Mar; 6(1): 31 14. F.DegenhardtF.StehleO.Kayser , “Chapter 2 - The Biosynthesis of Cannabinoids”, Handbook of Cannabis and Related Pathologies, 2017, Pages 13-23 15. Russo EB1, Marcu J2. , “Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads”, Adv Pharmacol. 2017;80:67-134 16. Russo E, “Cannabidiol Claims and Misconceptions”, Trends in Pharmacological Sciences 38(3) · January 2017 17. Ethan B Russo, Taming THC: potential cannabis synergy and phytocannabinoid- terpenoid entourage effects, Br J Pharmacol. 2011 Aug; 163(7): 1344–1364. 18. Adams TB, Taylor SV. Safety evaluation of essential oils: a constituent-based approach. In: Baser KHC, Buchbauer G, editors. Handbook of Essential Oils: Science, Technology, and Applications. Boca Raton, FL: CRC Press; 2010. pp. 185–208 19. Buchbauer G et Al, Fragrance compounds and essential oils with sedative effects upon inhalation, J Pharm Sci. 1993 Jun;82(6):660-4. 20. Viola Brugnatelli, Anti-inflammatory & anti-nociceptive properties of β-myrcene, https://www.fundacion-canna.es/en/anti-inflammatory-anti-nociceptive-properties- v-myrcene 21. Lewis MA1, Russo EB2, Smith KM1, Pharmacological Foundations of Cannabis Chemovars, Planta Med. 2018 Mar;84(4):225-233 22. RossanaRossi et Al, Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex, Journal of Pharmaceutical and Biomedical Analysis, Volume 50, Issue 2, 8 September 2009, Pages 224- 227 23. Bonamin F, Moraes TM, Dos Santos RC, et al. The effect of a minor constituent of essential oil from Citrus aurantium: the role of β-myrcene in preventing peptic ulcer disease. Chem Biol Interact. 2014;212:11-9 24. Natasha R. Ryz, David J. Remillard, and Ethan B. Russo.Cannabis and Cannabinoid Research.Dec 2017.ahead of printhttp://doi.org/10.1089/can.2017.0028 25. Tipparat, Prapatsorn & Kunkaew, Weerapun & Julsrigival, S. & Pinmanee, Saichon & Natakankitkul, Surapol. (2014). Classification of cannabis plants grown in Northern Thailand using physico-chemical properties. J. Nat. Sci. Res.. 4. 46-54. 26. Somkhid Thichak*[a] et Al, Identification of Drug-Type and Fiber-Type of Hemp (Cannabis sativa L.) by Multiplex PCR, Chiang Mai J. Sci. 2011; 38(4) : 608-618 27. Chemotype, sciencedirect, https://www.sciencedirect.com/topics/immunology- and-microbiology/chemotype 28. Latta, R.P. & Eaton, Seasonal fluctuations in cannabinoid content of Kansas Marijuana 29. , B.J. Econ Bot (1975) 29: 153. https://doi.org/10.1007/BF02863315 30. Mark A. Lewis et Al, Pharmacological Foundations of Cannabis Chemovars, Planta Med 2018; 84 (04): 225-233 31. Arno Hazekamp, Katerina Tejkalová, and Stelios Papadimitriou.Cannabis and Cannabinoid Research.Dec 2016.ahead of printhttp://doi.org/10.1089/can.2016.0017 32. Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. Front Plant Sci. 2019;9:1969. Published 2019 Jan 9. doi:10.3389/fpls.2018.01969 33. Philippe Henry PhD , Cannabis chemovar classification: terpenes hyper-classes and targeted genetic markers for accurate discrimination of flavours and effects, https://peerj.com/preprints/3307.pdf 34. Sawler J, Stout JM, Gardner KM, et al. The Genetic Structure of Marijuana and Hemp. PLoS One. 2015;10(8):e0133292. Published 2015 Aug 26. doi:10.1371/journal.pone.0133292
Chapter 4
1. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006 Feb;27(1):1-93. Epub 2005 Aug 18. Review. PubMed PMID: 16105678) 2. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol. 2007;5(2):81–97. doi:10.2174/157015907780866910 3. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biological Psychiatry 2016;79(7):516‐25. 4. Anandamide, Science Direct, https://www.sciencedirect.com/topics/neuroscience/anandamide 5. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805. doi:10.1111/bph.13250 6. Laprairie RB et Al, Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol. 2015 Oct;172(20):4790-805. 7. R B Laprairie et Al, Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor, https://www.theroc.us/researchlibrary/Cannabidiol%20is%20a%20negative%20al losteric%20modulator%20of%20the%20type%201%20cannabinoid%20receptor. pdf 8. Paula Morales, Pilar Goya, Nadine Jagerovic, and Laura Hernandez-Folgado, AllosteriModulators of the CB1 Cannabinoid Receptor: A Structural Update Review , Cannabis and Cannabinoid Research.Dec 2016.ahead of printhttp://doi.org/10.1089/can.2015.0005 9. Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A., & Shohami, E. (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. Journal of Cerebral Blood Flow & Metabolism, 25(4), 477–484. https://doi.org/10.1038/sj.jcbfm.9600047 10. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology. 2004 Dec;47(8):1170-9. PubMed PMID: 15567426.
11. Cabral GA, Griffin‐Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine 2009;11:E3 12. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Annals of the New York Academy of Sciences 2008;1139:434‐49 13. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy‐ induced apoptosis through the PI3K/Akt pathway. Journal of Neuroscience 2009;29(14):4564‐70 14. Ehrhart J, Obergon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of CB2 suppresses microglial activation. Journal of Neuroinflammation 2005;2:29 15. Evans FJ. Cannabinoids: the separation of central from peripheral effects on astructural basis. Planta Med. 1991 Oct;57(7):S60-7. Review. PubMed PMID: 1659702. 16. Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ., Molecular Targets of Cannabidiol in Neurological Disorders., Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3. Review. 17. Gonçalves J, Rosado T, Soares S, et al. Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines (Basel). 2019;6(1):31. Published 2019 Feb 23. doi:10.3390/medicines6010031 18. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handbook of Experimental Pharmacology 2005;168:327‐65 19. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacological Reviews 2010;62(4):588‐631 20. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinion on Investigational Drugs 2002;11:1365‐74 21. Silvestri C, Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism 2013;17(4):475‐90 22. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal 2005;7(3):e625‐54. 23. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends in Biochemical Sciences 2010;35(11):601‐8 24. Ligresti A, Petrosino S, Di Marzo V., From endocannabinoid profiling to 'endocannabinoid therapeutics'., Curr Opin Chem Biol. 2009 Jun;13(3):321-31. doi: 10.1016/j.cbpa.2009.04.615. Epub 2009 Jun 3. Review. 25. Lucie Geurts1 et all, Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue, Front. Microbiol., 13 July 2011 | https://doi.org/10.3389/fmicb.2011.00149 26. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? NatRev Drug Discov. 2008 May;7(5):438-55. doi: 10.1038/nrd2553. Review. PubMed PMID:18446159. 27. Cristoforo Silvestri, Vincenzo Di Marzo, The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders,Cell Metabolism,Volume 17, Issue 4,2013, 28. Di Marzo, V. Diabetologia, The endocannabinoid system in obesity and type 2 diabetes (2008) 51: 1356. https://doi.org/10.1007/s00125-008-1048-2 29. Philippe Coulon , Tightrope or Slackline? The Neuroscience of Psychoactive Substances, Trends in Pharmacological Sciences, July 2016, Vol. 37, No. 7 30. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002 Oct;56(8):365-79. Review. PubMed PMID: 12442909.
Chapter 5 1. CANNABIDIOL (CBD) Pre-Review Report, World Health Organization, https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf 2. Ruth Gallily1, Zhannah Yekhtin1, Lumír Ondřej Hanuš2 ,Overcoming the Bell‐ Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol, Pharmacology & Pharmacy, 2015, 6, 75‐85 3. Zgair A, Wong JC, Lee JB, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016;8(8):3448–3459. Published 2016 Aug 15. 4. Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls. Epilepsy Curr. 2014;14(5):250–252. doi:10.5698/1535-7597-14.5.250 5. Ethan Russo MD (2002) Cannabis Treatments in Obstetrics and Gynecology: A Historical Review, Journal of Cannabis Therapeutics, 2:3-4, 5-35, DOI: 10.1300/J175v02n03_02 6. ElSohly M, A, Gul W, Walker L, A: Pharmacokinetics and Tolerability of Δ9-THC- Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of Δ9-THC. Med Cannabis Cannabinoids 2018;1:44-53. doi: 10.1159/000489037 7. Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls. Epilepsy Curr. 2014;14(5):250–252. doi:10.5698/1535-7597-14.5.250 8. Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol 2013;209:573.e1-15. 9. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804. doi:10.1002/cbdv.200790152 10. John M. McPartland , Adulteration of cannabis with tobacco, calamus, and other cholinergic compounds, Cannabinoids 2008;3(4):16-20 11. Ethan B Russo, Taming THC: potential cannabis synergy and phytocannabinoid- terpenoid entourage effects, Br J Pharmacol. 2011 Aug; 163(7): 1344–1364. 12. M. O. Bonn-Miller, M. J. E. Loflin, B. F. Thomas, J. P. Marcu, T. Hyke, and R. Vandrey, “Labeling Accuracy of Cannabidiol Extracts Sold Online,” JAMA, vol. 318, no. 17, p. 1708, Nov. 2017. 13. B. F. Thomas and M. A. ElSohly, The analytical chemistry of cannabis : quality assessment, assurance, and regulation of medicinal marijuana and cannabinoid preparations.
14. J. Lydon and A. H. Teramura, “Photochemical decomposition of cannabidiol in its resin base,” Phytochemistry, vol. 26, no. 4, pp. 1216– 1217, Jan. 1987. 15. C. Citti, G. Ciccarella, D. Braghiroli, C. Parenti, M. A. Vandelli, and G. Cannazza, “Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method,” J. Pharm. Biomed. Anal., vol. 128, pp. 201–209, Sep. 2016.
16. MHRA, “MHRA statement on products containing Cannabidiol (CBD) - GOV.UK.” [Online]. Available: https://www.gov.uk/government/news/mhra- statement-on-products-containing-cannabidiol-cbd. 17. Giese et al.: Journal of AOAC International Vol. 98, No. 6, 2015. https://cannabis.gentechscientific.com/files/Method-for-the-Analysis-of- Cannabinoids-and-Terpenes-in-Cannabis.pdf 18. Cannabis testing and analysis [Online]. Available: https://www.labcompare.com/Cannabis-Testing-and-Analysis/ 19. The Highs and Lows of Cannabis Testing [Online]. Available: https://www.aocs.org/stay-informed/inform-magazine/featured-articles/the- highs-and-lows-of-cannabis-testing-october-2016 20. Bo Angela Wan et Al, Efficacy of different varieties of medical cannabis in relieving symptoms, J Pain Manage 2017;10(4):375-383
21. RalphKarlerWilliamCelyStuart A.Turkanis, Anticonvulsant properties of Δ9- tetrahydrocannabinol and other cannabinoids, Life Sciences Volume 15, Issue 5, 1 September 1974, Pages 931-947
Chapter 6
1. (J Transplant. 2019 Oct;19(10):2944-2948. doi: 10.1111/ajt.15398. Epub 2019 May 21. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Leino AD1, Emoto C2,3, Fukuda T2,3, Privitera M4, Vinks AA2,3, Alloway RR1)
2. Grayson L, Vines B, Nichol K, Szaflarski JP; UAB CBD Program. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2017;9:10–11. Published 2017 Oct 12. doi:10.1016/j.ebcr.2017.10.001 3. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6(1):69–75. doi:10.1016/j.cgh.2007.10.021 4. Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005 Jul;42(1):63-71. Erratum in: Hepatology. 2005 Aug;42(2):506. Pawlostky, Jean-Michel [corrected to Pawlotsky, Jean-Michel]. PubMed PMID: 15892090
5. Andrade C. Cannabis and neuropsychiatry, 1: benefits and risks. J ClinPsychiatry. 2016 May;77(5):e551-4. doi: 10.4088/JCP.16f10841. Review. PubMedPMID: 27249079. 6. Sebahat Tekeli Şengül; et Al, Cannabis-Induced Ventricular Tachycardia Leading to Death in an Old Man ,The American Journal of Cardiology; New York, (Apr 15, 2018) Vol. 121, Iss. 8, 7. Olaf H.DrummerAOaDimitriGerostamoulosabNoel W.Woodfordab Cannabis as a cause of death: A review, Forensic Science International Volume 298, May 2019, Pages 298-306 8. Kariyanna PT, Wengrofsky P, Jayarangaiah A, Haseeb S, Salciccioli L, et al. (2019) Marijuana and Cardiac Arrhythmias: A Scoping Study. Int J Clin Res Trials 4: 132. doi: https://doi.org/10.15344/2456-8007/2019/132 9. Kalla, Aditi et Al,Cannabis use predicts risks of heart failure and cerebrovascular accidents, Journal of Cardiovascular Medicine: September 2018 - Volume 19 - Issue 9 - p 480–484 10. John R. Richards, Mary L. Bing, Aimee K. Moulin, Joshua W. Elder, Robert T. Rominski, Phillip J. Summers & Erik G. Laurin (2019) Cannabis use and acute coronary syndrome, Clinical Toxicology, 57:10, 831-841, DOI: 10.1080/15563650.2019.1601735 11. Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison inthe in vitro inhibitory effects of major phytocannabinoids and polycyclicaromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9activity. Drug Metab Pharmacokinet. 2012;27(3):294-300. Epub 2011 Dec 13. PubMed PMID: 22166891. 12. Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, HuestisMA. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoidswith and without Alcohol. Clin Chem. 2015 Jun;61(6):850-69. doi:10.1373/clinchem.2015.238287. Epub 2015 May 27. PubMed PMID: 26019183. 13. Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, GaffneyG, Huestis MA. Cannabis effects on driving lateral control with and withoutalcohol. Drug Alcohol Depend. 2015 Sep 1;154:25-37. doi:10.1016/j.drugalcdep.2015.06.015. Epub 2015 Jun 23. PubMed PMID: 26144593; PubMedCentral PMCID: PMC4536116. 14. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, andinducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev.2014 Feb;46(1):86-95. doi: 10.3109/03602532.2013.849268. Epub 2013 Oct 25.Review. PubMed PMID: 24160757. 15. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction betweenclobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015Aug;56(8):1246-51. doi: 10.1111/epi.13060. Epub 2015 Jun 26. PubMed PMID:26114620. 16. Taha, S. Talhamy, M. Wollner, A. Peer, G. Bar-Sela, 1545PD The effect of cannabis use on tumor response to nivolumab in patients with advanced malignancies, Annals of Oncology, Volume 28, Issue suppl_5, September 2017, mdx388.005
Chapter 7
1. Gruber SA, Sagar KA, Dahlgren MK, Gonenc A, Smith RT, Lambros AM, Cabrera KB, Lukas SE. The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment. FrontPharmacol. 2018 Jan 17;8:983. doi: 10.3389/fphar.2017.00983. eCollection 2017.PubMed PMID: 29387010; PubMed Central PMCID: PMC5776082. 2. University of Bonn. "Cannabis reverses aging processes in the brain, study suggests: Researchers restore the memory performance of Methuselah mice to a juvenile stage." ScienceDaily. ScienceDaily, 8 May 2017.
21a José Martínez Orgado, Javier Fernández-Ruiz & Julián Romero (2009) The endocannabinoid system in neuropathological states, International Review of Psychiatry, 21:2, 172- 180, DOI: 10.1080/09540260902782828
22. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. The endocannabinoid systemand neurogenesis in health and disease. Neuroscientist. 2007 Apr;13(2):109-14.Review. PubMed PMID: 17404371. 23. Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, YamamuraT, Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may bemore relevant to multiple sclerosis. J Neuroimmunol. 2008 Jan;193(1-2):120-9.Epub 2007 Nov 26. PubMed PMID: 18037503 24. Sánchez AJ, García-Merino A. Neuroprotective agents: cannabinoids. ClinImmunol. 2012 Jan;142(1):57-67. doi: 10.1016/j.clim.2011.02.010. Epub 2011 Mar21. Review. PubMed PMID: 21420365 25. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V,Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M. Theendocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007 Oct;130(Pt 10):2543- 53. Epub 2007 Jul11. PubMed PMID: 17626034. 26. de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J.Cannabinoids ameliorate disease progression in a model of multiple sclerosis inmice, acting preferentially through CB1 receptor-mediated anti-inflammatoryeffects. Neuropharmacology. 2012 Jun;62(7):2299-308. doi:10.1016/j.neuropharm.2012.01.030. Epub 2012 Feb 8. PubMed PMID: 22342378. 27. Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G. The biology thatunderpins the therapeutic potential of cannabis-based medicines for the controlof spasticity in multiple sclerosis. Mult Scler Relat Disord. 2012Apr;1(2):64-75. doi: 10.1016/j.msard.2011.11.001. Epub 2012 Jan 18. Review.PubMed PMID: 25876933. 27a. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12. PubMed PMID: 19910459; PubMed Central PMCID: PMC2804319.
27b. Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007 Nov;152(5):649-54. Epub 2007 Sep 24. Review. PubMed PMID: 17891167; PubMed Central PMCID: PMC2190016.
28. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N,Farrell M. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018 Feb13;18(2):8. doi: 10.1007/s11910-018-0814-x. Review. PubMed PMID: 29442178. 29. Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoidsystem and its therapeutic exploitation in multiple sclerosis: Clues for otherneuroinflammatory diseases. Prog Neurobiol. 2018 Jan;160:82-100. doi:10.1016/j.pneurobio.2017.10.007. Epub 2017 Oct 31. Review. PubMed PMID: 29097192. 30. Schabas AJ, Vukojevic V, Taylor C, Thu Z, Badyal A, Chan JK, Devonshire V,Traboulsee A, Sayao AL, Carruthers R. Cannabis-based product use in a multiplesclerosis cohort. Mult Scler J Exp Transl Clin. 2019 Sep 31. Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploringcannabis use by patients with multiple sclerosis in a state where cannabis islegal. Mult Scler Relat Disord. 2019 Jan;27:383-390. doi:10.1016/j.msard.2018.11.022. Epub 2018 Nov 20. PubMed PMID: 30502644 32. Rudroff T, Sosnoff J. Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Front Neurol. 2018;9:183. Published 2018 Mar 22. doi:10.3389/fneur.2018.00183 33. Patel RS, Kamil S, Shah MR, Bhimanadham NN, Imran S. Pros and Cons of Marijuana in Treatment of Parkinson's Disease. Cureus. 2019;11(6):e4813. Published 2019 Jun 3. doi:10.7759/cureus.4813 34. Mainka T, Stork J, Hidding U, Buhmann C. [Cannabis in Parkinson's Disease: Hype or help?] Fortschritte der Neurologie-psychiatrie. 2018 Feb;86(2):106-116. DOI: 10.1055/s-0043-120668. 35. Mohanty D, Lippmann S. Marijuana for Parkinson's Disease?. Innov Clin Neurosci. 2019;16(1-2):33– 34. 36. Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Iscannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? EurArch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi:10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Review. PubMed PMID: 30706171. 37. Dementia UK report, https://www.alzheimers.org.uk/about-us/policy-and- influencing/dementia-uk-report 38. 2019 ALZHEIMER’S DISEASE FACTS AND FIGURES , https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
38a Dale Brenesen https://www.apollohealthco.com/dr-bredesen/
39. Baron EP. Comprehensive Review of Medicinal Marijuana, Cannabinoids, andTherapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25. Review. PubMed PMID: 26015168. 40. Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P. Efficacy ofCannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease.Mol Neurobiol. 2019 Nov;56(11):7719-7730. doi: 10.1007/s12035-019-1637-8. Epub2019 May 19. PubMed PMID: 31104297; PubMed Central PMCID: PMC6815693. 41. Eggers C, Fujitani M, Kato R, Smid S. Novel cannabis flavonoid, cannflavin Adisplays both a hormetic and neuroprotective profile against amyloid β-mediatedneurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone anddiplacone. Biochem Pharmacol. 2019 Nov;169:113609. doi:10.1016/j.bcp.2019.08.011. Epub 2019 Aug 19. PubMed PMID: 31437460. 42. Hughes B, Herron CE. Cannabidiol Reverses Deficits in Hippocampal LTP in aModel of Alzheimer's Disease. Neurochem Res. 2019 Mar;44(3):703-713. doi:10.1007/s11064-018-2513-z. Epub 2018 Mar 24. PubMed PMID: 29574668. 43. Tampi RR, Young JJ, Tampi DJ. Cannabinoids for the treatment of behavioral andpsychological symptoms of dementia. Neurodegener Dis Manag. 2018Aug;8(4):211-213. doi: 10.2217/nmt- 2018-0019. Epub 2018 Jul 24. Review. PubMedPMID: 30040030. 44. Broers, Barbara & Patà, Zacharie & Mina, Aline & Wampfler, James & de Saussure, Christian & Pautex, Sophie. (2019). Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva. Medical Cannabis and Cannabinoids. 1-4. 10.1159/000498924. 45. Palace ZJ, Reingold DA. Medical Cannabis in the Skilled Nursing Facility: ANovel Approach to Improving Symptom Management and Quality of Life. J Am Med Dir Assoc. 2019 Jan;20(1):94- 98. doi: 10.1016/j.jamda.2018.11.013. PubMed PMID:30580820. 46. Hillen JB, Soulsby N, Alderman C, Caughey GE. Safety and effectiveness ofcannabinoids for the treatment of neuropsychiatric symptoms in dementia: asystematic review. Ther Adv Drug Saf. 2019 May 15;10:2042098619846993. doi:10.1177/2042098619846993. eCollection 2019. Review. PubMed PMID: 31205674; PubMedCentral PMCID: PMC6535742.
Chapter 8
1a Book Wh Zebras don’t get ulcers - https://www.amazon.co.uk/Why-Zebras-Dont-Ulcers- Revised/dp/0805073698
1. Lohr JB, Chang H, Sexton M, Palmer BW. Allostatic load and the cannabinoidsystem: implications for the treatment of physiological abnormalities inpost-traumatic stress disorder (PTSD). CNS Spectr. 2019 Jul 15:1-7. doi:10.1017/S1092852919001093. [Epub ahead of print] PubMed PMID: 31303187. 2. Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J,Ortega-Gutiérrez S, Vázquez-Villa H, Moreira FA, Guzmán M, Galve-Roperh I,Guimarães FS. The anxiolytic effect of cannabidiol on chronically stressed micedepends on hippocampal neurogenesis: involvement of the endocannabinoid system.Int J Neuropsychopharmacol. 2013 Jul;16(6):1407-19. doi:10.1017/S1461145712001502. Epub 2013 Jan 9. PubMed PMID: 23298518. 3. Fogaça MV, Campos AC, Coelho LD, Duman RS, Guimarães FS. The anxiolyticeffects of cannabidiol in chronically stressed mice are mediated by theendocannabinoid system: Role of neurogenesis and dendritic remodeling.Neuropharmacology. 2018 Jun;135:22-33. doi: 10.1016/j.neuropharm.2018.03.001.Epub 2018 Mar 3. PubMed PMID: 29510186. 4. Akirav I. Cannabinoids and glucocorticoids modulate emotional memory afterstress. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2554-63. doi:10.1016/j.neubiorev.2013.08.002. Epub 2013 Aug 14. Review. PubMed PMID: 23954749. 5. Maes M, Coucke F, Leunis JC. Normalization of the increased translocation ofendotoxin from gram negative enterobacteria (leaky gut) is accompanied by aremission of chronic fatigue syndrome. Neuro Endocrinol Lett. 2007Dec;28(6):739-44. PubMed PMID: 18063928. 6. De Laurentiis A, Fernandez-Solari J, Mohn C, Burdet B, Zorrilla Zubilete MA,Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. JNeuroimmunol. 2010 Apr 15;221(1-2):32- 41. doi: 10.1016/j.jneuroim.2010.02.006.Epub 2010 Mar 5. PubMed PMID: 20207018 7. Corroon J, Felice JF. The Endocannabinoid System and its Modulation byCannabidiol (CBD). Altern Ther Health Med. 2019 Jun;25(S2):6-14. PubMed PMID:31202198. 8. Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brainageing. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3326-41. doi:10.1098/rstb.2011.0388. Review. PubMed PMID: 23108550; PubMed Central PMCID:PMC3481530.
Chapter 9 1. Adult Psychiatric Morbidity Survey,https://digital.nhs.uk/data-and- information/publications/statistical/adult-psychiatric-morbidity-survey/adult- psychiatric-morbidity-survey-survey-of-mental-health-and-wellbeing-england-2014 2. Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: anUpdate. Curr Psychiatry Rep. 2019 Apr 27;21(6):38. doi:10.1007/s11920-019-1026-z. Review. PubMed PMID: 31030284; PubMed Central PMCID:PMC6486906. 3. Achermann P, Borbély AA. Dynamics of EEG slow wave activity duringphysiological sleep and after administration of benzodiazepine hypnotics. HumNeurobiol. 1987;6(3):203-10. PubMed PMID: 2896653 4. Gevins AS, Stone RK, Ragsdale SD. Differentiating the effects of threebenzodiazepines on non- REM sleep EEG spectra. A neural-network patternclassification analysis. Neuropsychobiology. 1988;19(2):108-15. PubMed PMID:2906410. 5. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can'tescape their sleeping pills. Acta Psychiatr Scand. 1988 Dec;78(6):706-11. PubMed PMID: 2906215. 6. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanismsinvolved in the large-spectrum therapeutic potential of cannabidiol inpsychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review. PubMed PMID: 23108553; PubMed Central PMCID: PMC3481531
7. Zuardi, Antonio & Cosme, RA & Graeff, Frederico & Guimarães, Francisco. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of psychopharmacology (Oxford, England). 7. 82-8. 10.1177/026988119300700112. 8. Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol.Curr Neuropharmacol. 2017;15(2):291-299. Review. PubMed PMID: 27157263; PubMedCentral PMCID: PMC5412699.
9. Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety,mood, and related disorders ready for prime time? Depress Anxiety. 2017Nov;34(11):1006-1017. doi: 10.1002/da.22664. Epub 2017 Jun 21. Review. PubMedPMID: 28636769. 10. Madras, Bertha. (2018). Tinkering with THC-to-CBD ratios in Marijuana. Neuropsychopharmacology. 44. 1. 10.1038/s41386-018-0217-3.
11. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. doi:10.7812/TPP/18-041
12. Galea S, Nandi A, Vlahov D. The epidemiology of post-traumatic stress disorderafter disasters. Epidemiol Rev. 2005;27:78-91. Review. PubMed PMID: 15958429. 13. Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment ofPost-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019Apr;25(4):392-397. doi: 10.1089/acm.2018.0437. Epub 2018 Dec 13. PubMed PMID:30543451; PubMed Central PMCID: PMC6482919. 14. Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, Phan KL.Cannabinoid modulation of prefrontal-limbic activation during fear extinctionlearning and recall in humans. Neurobiol Learn Mem. 2014 Sep;113:125-34. doi:10.1016/j.nlm.2013.09.009. Epub 2013 Sep 19. PubMed PMID: 24055595; PubMedCentral PMCID: PMC3960373. 15. Ney LJ, Matthews A, Bruno R, Felmingham KL. Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. Neurosci Biobehav Rev. 2018 Nov;94:302-320. doi: 10.1016/j.neubiorev.2018.07.006. Epub2018 Jul 11. Review. PubMed PMID: 30017748. 16. Berardi A, Schelling G, Campolongo P. The endocannabinoid system and PostTraumatic Stress Disorder (PTSD): From preclinical findings to innovativetherapeutic approaches in clinical settings. Pharmacol Res. 2016 Sep;111:668-678.doi: 10.1016/j.phrs.2016.07.024. Epub 2016 Jul 22. Review. PubMed PMID: 27456243. 17. Trezza V, Campolongo P. The endocannabinoid system as a possible target totreat both the cognitive and emotional features of post-traumatic stress disorder(PTSD). Front Behav Neurosci. 2013 Aug 9;7:100. doi: 10.3389/fnbeh.2013.00100.eCollection 2013. PubMed PMID: 23950739; PubMed Central PMCID: PMC3739026. 18. Ney LJ, Matthews A, Bruno R, Felmingham KL. Cannabinoid interventions forPTSD: Where to next? Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul13;93:124-140. doi: 10.1016/j.pnpbp.2019.03.017. Epub 2019 Apr 1. Review. PubMed PMID: 30946942. 19. Loflin MJ, Babson KA, Bonn-Miller MO. Cannabinoids as therapeutic for PTSD.Curr Opin Psychol. 2017 Apr;14:78-83. doi: 10.1016/j.copsyc.2016.12.001. Epub2016 Dec 25. Review. PubMed PMID: 28813324. 20. Rabinak CA, Peters C, Marusak HA, Ghosh S, Phan KL. Effects of acuteΔ9-tetrahydrocannabinol on next-day extinction recall is mediated bypost-extinction resting-state brain dynamics. Neuropharmacology. 2018Dec;143:289-298. doi: 10.1016/j.neuropharm.2018.10.002. Epub 2018 Oct 3. PubMedPMID: 30291940; PubMed Central PMCID: PMC6269194.
21. Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Braz JPsychiatry. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese. PubMedPMID: 22729452 22. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a PotentialTreatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct;12(4):825-36. doi:10.1007/s13311-015- 0387-1. Review. PubMed PMID: 26341731; PubMed Central PMCID:PMC4604171. 23. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoidmodulation of amygdala reactivity to social signals of threat in humans. JNeurosci. 2008 Mar 5;28(10):2313-9. doi: 10.1523/JNEUROSCI.5603-07.2008. PubMedPMID: 18322078; PubMed Central PMCID: PMC2657360. 24. Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, Phan KL.Cannabinoid modulation of prefrontal-limbic activation during fear extinctionlearning and recall in humans. Neurobiol Learn Mem. 2014 Sep;113:125-34. doi:10.1016/j.nlm.2013.09.009. Epub 2013 Sep 19. PubMed PMID: 24055595; PubMedCentral PMCID: PMC3960373. 25. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018;9:2009. Published 2018 Sep 21. doi:10.3389/fimmu.2018.02009 26. Andrade AK, Renda B, Murray JE. Cannabinoids, interoception, and anxiety.Pharmacol Biochem Behav. 2019 May;180:60-73. doi: 10.1016/j.pbb.2019.03.006. Epub2019 Mar 25. PubMed PMID: 30922834.
Chapter 10 – Low mood and depression
1. Rakel, D. Integrative Medicine 3rd Edition 2012 pp26. 2. García, Oscar & Rueda-Orozco, Pavel & Amancio-Belmont, Octavio & Ruiz-Contreras, Alejandra & Méndez-Díaz, Mónica. (2017). An integrative overview of the cannabinergic system and mental health. Salud Mental. 40. 119-128. 10.17711/SM.0185-3325.2017.015. 3. Mori MA, Meyer E, Soares LM, Milani H, Guimarães FS, de Oliveira RMW.Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functionalrecovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 2017Apr 3;75:94-105. doi: 10.1016/j.pnpbp.2016.11.005. Epub 2016 Nov 23. PubMed PMID:27889412. 4. Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Cannabidiol induces rapid-acting antidepressant-like effects andenhances cortical 5- HT/glutamate neurotransmission: role of 5-HT1A receptors.Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017.Epub 2015 Dec 19. PubMed PMID: 26711860. 5. Schiavon AP, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM.Influence of single and repeated cannabidiol administration on emotional behaviorand markers of cell proliferation and neurogenesis in non-stressed mice. ProgNeuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:27-34. doi:10.1016/j.pnpbp.2015.06.017. Epub 2015 Jul 14. PubMed PMID: 26187374. 6. Shbiro L, Hen-Shoval D, Hazut N, Rapps K, Dar S, Zalsman G, Mechoulam R,Weller A, Shoval G. Effects of cannabidiol in males and females in two different rat models of depression. Physiol Behav. 2019 Mar 15;201:59-63. doi:10.1016/j.physbeh.2018.12.019. Epub 2018 Dec 17. PubMed PMID: 30571957. 7. Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj CG, Mechoulam R, Zalsman G,Weller A, Shoval G. Acute oral cannabidiolic acid methyl ester reducesdepression-like behavior in two genetic animal models of depression. Behav Brain Res. 2018 Oct 1;351:1-3. doi: 10.1016/j.bbr.2018.05.027. Epub 2018 May 31. PubMedPMID: 29860002 8. Hartmann A, Lisboa SF, Sonego AB, Coutinho D, Gomes FV, Guimarães FS.Cannabidiol attenuates aggressive behavior induced by social isolation in mice:Involvement of 5-HT1A and CB1 receptors. Prog Neuropsychopharmacol BiolPsychiatry. 2019 Aug 30;94:109637. doi: 10.1016/j.pnpbp.2019.109637. Epub 2019May 2. PubMed PMID: 31054943 9. Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C, Florensa-Zanuy E, Díaz Á, UrigüenL, Castro E, Pazos A, Callado LF. The endocannabinoid system in mental disorders:Evidence from human brain studies. Biochem Pharmacol. 2018 Nov;157:97-107. doi:10.1016/j.bcp.2018.07.009. Epub 2018 Jul 17. Review. PubMed PMID: 30026022. 10. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationshipbetween cannabis use and psychosis. Drug Alcohol Depend. 2003 Jul 20;71(1):37-48.PubMed PMID: 12821204. 11. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–1213. doi:10.1136/bmj.325.7374.1212 12. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use andpsychosis: a longitudinal population-based study. Am J Epidemiol. 2002 Aug15;156(4):319-27. PubMed PMID: 12181101. 13. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J.Prospective cohort study of cannabis use, predisposition for psychosis, andpsychotic symptoms in young people. BMJ. 2005 Jan 1;330(7481):11. Epub 2004 Dec1. PubMed PMID: 15574485; PubMed Central PMCID: PMC539839. 14. Abush H, Ghose S, Van Enkevort EA, Clementz BA, Pearlson GD, Sweeney JA,Keshavan MS, Tamminga CA, Ivleva EI. Associations between adolescent cannabis useand brain structure in psychosis. Psychiatry Res Neuroimaging. 2018 Jun30;276:53-64. doi: 10.1016/j.pscychresns.2018.03.008. Epub 2018 Mar 28. PubMedPMID: 29628270; PubMed Central PMCID: PMC5959798. 15. Hanna RC, Shalvoy A, Cullum CM, Ivleva EI, Keshavan M, Pearlson G, Hill SK,Sweeney JA, Tamminga CA, Ghose S. Cognitive Function in Individuals WithPsychosis: Moderation by Adolescent Cannabis Use. Schizophr Bull. 2016Nov;42(6):1496-1503. doi: 10.1093/schbul/sbw030. Epub 2016 Mar 31. PubMed PMID:27033329; PubMed Central PMCID: PMC5049522. 16. Galindo L, Moreno E, López-Armenta F, Guinart D, Cuenca-Royo A,Izquierdo-Serra M, Xicota L, Fernandez C, Menoyo E, Fernández-Fernández JM,Benítez-King G, Canela EI, Casadó V, Pérez V, de la Torre R, Robledo P. Cannabis Users Show Enhanced Expression of CB(1)-5HT(2A) Receptor Heteromers in Olfactory Neuroepithelium Cells. Mol Neurobiol. 2018 Aug;55(8):6347-6361. doi:10.1007/s12035-017-0833-7. Epub 2018 Jan 2. PubMed PMID: 29294249. 17. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J,Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviatespsychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20;2:e94. doi:10.1038/tp.2012.15. PubMed PMID: 22832859; PubMed Central PMCID: PMC3316151. 18. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015 Mar;162(1-3):153-61. doi:10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review. PubMed PMID: 25667194. 19. C.FerreiraS.AlvesC.OliveiraM.J.Avelino, Is borderline personality disorder a neuroendocrine disease? European Psychiatry, Volume 41, Supplement, April 2017, Pages S631-S632
Chapter 11 - sleep
1. As many as 16 million UK adults* are suffering from sleepless nights as a third (31%) say they have insomnia. https://www.aviva.com/newsroom/news-releases/2017/10/Sleepless-cities- revealed-as-one-in-three-adults-suffer-from-insomnia/ 2. Barclay NL, Ellis JG. Sleep-related attentional bias in poor versus goodsleepers is independent of affective valence. J Sleep Res. 2013 Aug;22(4):414-21.doi: 10.1111/jsr.12035. Epub 2013 Feb 9. PubMed PMID: 23398166. 3. Yang HC, Suh S, Kim H, Cho ER, Lee SK, Shin C. Testing bidirectionalrelationships between marital quality and sleep disturbances: a 4-year follow-up study in a Korean cohort. J Psychosom Res. 2013 May;74(5):401-6. doi:10.1016/j.jpsychores.2013.01.005. Epub 2013 Mar 6. PubMed PMID: 23597327. 4. Lyytikäinen P, Lallukka T, Lahelma E, Rahkonen O. Sleep problems and majorweight gain: a follow-up study. Int J Obes (Lond). 2011 Jan;35(1):109-14. doi:10.1038/ijo.2010.113. Epub 2010 Jun 8. PubMed PMID: 20531352. 5. Vgontzas AN, Lin HM, Papaliaga M, Calhoun S, Vela-Bueno A, Chrousos GP, BixlerEO. Short sleep duration and obesity: the role of emotional stress and sleepdisturbances. Int J Obes (Lond). 2008 May;32(5):801-9. doi: 10.1038/ijo.2008.4.Epub 2008 Feb 5. PubMed PMID: 18253159 6. Kumari M, Badrick E, Ferrie J, Perski A, Marmot M, Chandola T. Self-reportedsleep duration and sleep disturbance are independently associated with cortisolsecretion in the Whitehall II study. J Clin Endocrinol Metab. 2009Dec;94(12):4801-9. doi: 10.1210/jc.2009-0555. Epub 2009 Oct 22. PubMed PMID:19850688; PubMed Central PMCID: PMC2795654. 7. Chen Y, Lyga J. Brain-skin connection: stress, inflammation and skin aging. Inflamm Allergy Drug Targets. 2014;13(3):177–190. doi:10.2174/1871528113666140522104422 8. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry. 1998 May1;43(9):687-93. PubMed PMID: 9583003. 9. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality?Sleep Med. 2009 Mar;10(3):279-86. doi: 10.1016/j.sleep.2008.12.004. Epub 2009 Mar9. PubMed PMID: 19269892. 10. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. Effectof anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospectivecohort study. BMJ. 2014 Mar 19;348:g1996. doi: 10.1136/bmj.g1996. PubMed PMID:24647164; PubMed Central PMCID: PMC3959619. 11. Belleville G. Mortality hazard associated with anxiolytic and hypnotic druguse in the National Population Health Survey. Can J Psychiatry. 2010Sep;55(9):558-67. PubMed PMID: 20840803. 12. Choi JW, Lee J, Jung SJ, Shin A, Lee YJ. Use of Sedative-Hypnotics andMortality: A Population- Based Retrospective Cohort Study. J Clin Sleep Med. 2018 Oct 15;14(10):1669-1677. doi: 10.5664/jcsm.7370. PubMed PMID: 30353805; PubMedCentral PMCID: PMC6175798. 13. Lovato N, Lack L. Insomnia and mortality: A meta-analysis. Sleep Med Rev. 2019Feb;43:71-83. doi: 10.1016/j.smrv.2018.10.004. Epub 2018 Nov 11. Review. PubMedPMID: 30529432. 14. Du Y, Wolf IK, Busch MA, Knopf H. Associations between the use of specificpsychotropic drugs and all-cause mortality among older adults in Germany: Resultsof the mortality follow-up of the German National Health Interview andExamination Survey 1998. PLoS One. 2019 Jan 14;14(1):e0210695. doi:10.1371/journal.pone.0210695. eCollection 2019. PubMed PMID: 30640945; PubMedCentral PMCID: PMC6331145. 15. Pava MJ, Makriyannis A, Lovinger DM. Endocannabinoid Signaling Regulates SleepStability. PLoS One. 2016 Mar 31;11(3):e0152473. doi:10.1371/journal.pone.0152473. eCollection 2016. PubMed PMID: 27031992; PubMedCentral PMCID: PMC4816426. 16. Murillo-Rodriguez E, Pastrana-Trejo JC, Salas-Crisóstomo M, de-la-Cruz M. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and LikelyDream Contents. CNS Neurol Disord Drug Targets. 2017;16(4):370-379. doi:10.2174/1871527316666170223161908. Review. PubMed PMID: 28240187. 17. Murillo-Rodriguez E, Poot-Ake A, Arias-Carrion O, Pacheco-Pantoja E,Fuente-Ortegon Ade L, Arankowsky-Sandoval G. The emerging role of theendocannabinoid system in the sleep-wake cycle modulation. Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):189-96. Review. PubMed PMID: 21919868. 18. Gorelick DA, Goodwin RS, Schwilke E, et al. Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. Am J Addict. 2013;22(5):510–514. doi:10.1111/j.1521- 0391.2013.12003.x 19. Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The useof cannabinoids for sleep: A critical review on clinical trials. Exp ClinPsychopharmacol. 2019 Aug;27(4):383-401. doi: 10.1037/pha0000285. Epub 2019 May23. PubMed PMID: 31120284. 20. Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Mechoulam R,Drucker-Colín R. Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci. 2011 Mar14;88(11-12):504-11. doi: 10.1016/j.lfs.2011.01.013. Epub 2011 Jan 22. PubMedPMID: 21262236. 21. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R,Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleepin rats. FEBS Lett. 2006 Aug 7;580(18):4337-45. Epub 2006 Jul 10. PubMed PMID:16844117.
21a Hsiao YT, Yi PL, Li CL, Chang FC. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012 Jan;62(1):373-84. doi: 10.1016/j.neuropharm.2011.08.013. Epub 2011 Aug 16. PubMed PMID: 21867717.
22. Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, SobreiraET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.Cannabidiol can improve complex sleep-related behaviours associated with rapideye movement sleep behaviour disorder in Parkinson's disease patients: a caseseries. J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179. Epub2014 May 21. PubMed PMID: 24845114. 23. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. doi:10.7812/TPP/18-041
24. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons fromtherapeutic clinical trials of Sativex, a cannabis-based medicine. ChemBiodivers. 2007 Aug;4(8):1729-43. Review. PubMed PMID: 17712817. 25. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect ofDelta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morningbehavior in young adults. J Clin Psychopharmacol. 2004 Jun;24(3):305-13. PubMedPMID: 15118485. 26. Cousens K, DiMascio A. (-) Delta 9 THC as an hypnotic. An experimental studyof three dose levels. Psychopharmacologia. 1973 Dec 20;33(4):355-64. PubMed PMID:4776660. 27. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi:10.1007/s11920-017-0775-9. Review. PubMed PMID: 28349316.
28. Nicole P Bowles, Maya X Herzig, Meera Bhide, Steven A Shea, 0130 Cannabis Use, Sleep, and Sleepiness: An Online Survey, Sleep, Volume 42, Issue Supplement_1, April 2019, Pages A53– A54 29. Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The useof cannabinoids for sleep: A critical review on clinical trials. Exp ClinPsychopharmacol. 2019 Aug;27(4):383-401. doi: 10.1037/pha0000285. Epub 2019 May23. PubMed PMID: 31120284. 30. Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act asperipheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019Aug;104:33-39. doi: 10.1016/j.archoralbio.2019.05.028. Epub 2019 May 28. PubMedPMID: 31158702. 31. Whoop Sleep App, https://www.whoop.com/the-locker/feature-update-whoop-app-sleep- coach/)
Chapter 11
1a Fayaz A, Croft P, Langford RM, et al
Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies BMJ Open 2016;6:e010364. doi: 10.1136/bmjopen-2015-010364
1. NIH, Symptoms Matter—Leading Causes of Disability, https://nccih.nih.gov/about/strategic- plans/2016/symptoms-matter-leading-causes-of-disability 2. Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain. Handb Exp Pharmacol. 2015;227:119-43. doi:10.1007/978-3-662-46450-2_7. Review. PubMed PMID: 25846617. 3. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4(4):e0022. Published 2013 Oct 29. doi:10.5041/RMMJ.10129 4. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C, DiMarzo V, Mangoni GS, Rossi F, Maione S. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with theserotonergic system. Eur J Neurosci. 2006 Oct;24(7):2011-20. Epub 2006 Oct 16.PubMed PMID: 17040473. 5. Burston JJ, Woodhams SG. Endocannabinoid system and pain: an introduction.Proc Nutr Soc. 2014 Feb;73(1):106-17. doi: 10.1017/S0029665113003650. Epub 2013Oct 22. Review. PubMed PMID: 24148358. 6. Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. Eur J Rheumatol. 2017;4(3):210–218. doi:10.5152/eurjrheum.2017.17025 7. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exerciseactivates the endocannabinoid system. Neuroreport. 2003 Dec 2;14(17):2209-11.PubMed PMID: 14625449. 8. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactivecannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007 Feb5;556(1-3):75-83. Epub 2006 Nov 10. PubMed PMID: 17157290. 9. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A)receptors without diminishing nervous system function or chemotherapy efficacy.Br J Pharmacol. 2014 Feb;171(3):636-45. doi: 10.1111/bph.12439. PubMed PMID:24117398; PubMed Central PMCID: PMC3969077. 10. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale forcombining tetrahydrocannabinol and cannabidiol. Med Hypotheses.2006;66(2):234-46. Epub 2005 Oct 4. PubMed PMID: 16209908. 11. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M,Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the artand new challenges for therapeutic applications. Pharmacol Ther. 2017Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Review.PubMed PMID: 28232276. 12. Beyond Delta-9-THC and CBD: Current Evidence for Medical Benefit of Terpenes and Less Studied Cannabinoids - http://www.cannabissciencetech.com/medical- cannabis/beyond-delta-9-thc-and-cbd-current-evidence-medical-benefit-terpenes-and-less- studied-cannabinoids 13. Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019 Aug;104:33-39. doi: 10.1016/j.archoralbio.2019.05.028. Epub 2019 May 28. PubMed PMID: 31158702.
14. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A)receptors without diminishing nervous system function or chemotherapy efficacy.Br J Pharmacol. 2014 Feb;171(3):636-45. doi: 10.1111/bph.12439. PubMed PMID:24117398; PubMed Central PMCID: PMC3969077.
Chapter 12 Women’s Health
1. Ethan Russo MD (2002) Cannabis Treatments in Obstetrics and Gynecology: A Historical Review, Journal of Cannabis Therapeutics, 2:3-4, 5-35, DOI: 10.1300/J175v02n03_02 2. WOMEN DOCTORS IN THE BRITISH HEALTH SERVICES, https://core.ac.uk/download/pdf/43950.pdf 3. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC.Localisation and function of the endocannabinoid system in the human ovary. PLoS One. 2009;4(2):e4579. doi: 10.1371/journal.pone.0004579. Epub 2009 Feb 24. PubMedPMID: 19238202; PubMed Central PMCID: PMC2640464. 4. Walker, O.S., Holloway, A.C. & Raha, S. The role of the endocannabinoid system in female reproductive tissues. J Ovarian Res 12, 3 (2019) doi:10.1186/s13048-018-0478-9 5. Krishnan S, Agrawal K, Tryon RR, Welch LC, Horn WF, Newman JW, Keim NL.Structural equation modeling of food craving across the menstrual cycle usingbehavioral, neuroendocrine, and metabolic factors. Physiol Behav. 2018 Oct15;195:28-36. doi: 10.1016/j.physbeh.2018.07.011. Epub 2018 Jul 18. PubMed PMID: 30031087; PubMed Central PMCID: PMC6251416. 6. Luschnig P, Schicho R: Cannabinoids in Gynecological Diseases. Med Cannabis Cannabinoids 2019;2:14-21. doi: 10.1159/000499164 7. Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999 Aug;60(2):489-96.Review. PubMed PMID: 10465224. 8. Burstein S, Levin E, Varanelli C. Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol. 1973 Nov 15;22(22):2905-10. PubMed PMID: 4202579.
8a Dr Aviva Romm https://avivaromm.com/about/
9. Shen X, Duan H, Wang S, Gan L, Xu Q, Li JJ. Decreased Expression ofCannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients withAdenomyosis. Biomed Res Int. 2019 Jan 20;2019:5468954. doi: 10.1155/2019/5468954.eCollection 2019. PubMed PMID: 30800671; PubMed Central PMCID: PMC6360557 10. Sanchez AM, Cioffi R, Viganò P, Candiani M, Verde R, Piscitelli F, Di Marzo V,Garavaglia E, Panina-Bordignon P. Elevated Systemic Levels of Endocannabinoidsand Related Mediators Across the Menstrual Cycle in Women With Endometriosis.Reprod Sci. 2016 Aug;23(8):1071-9. doi: 10.1177/1933719116630414. Epub 2016 Feb17. PubMed PMID: 26887427. 11. Bouaziz J, Bar On A, Seidman DS, Soriano D. The Clinical Significance of Endocannabinoids in Endometriosis Pain Management. Cannabis Cannabinoid Res. 2017;2(1):72–80. Published 2017 Apr 1. doi:10.1089/can.2016.0035 12. McHugh D, Page J, Dunn E, Bradshaw HB. Δ(9) -Tetrahydrocannabinol andN-arachidonyl glycine are full agonists at GPR18 receptors and induce migrationin human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24. doi: 10.1111/j.1476-5381.2011.01497.x. PubMed PMID: 21595653; PubMed Central PMCID:PMC3423258. 13. Sanchez AM, Quattrone F, Pannese M, Ulisse A, Candiani M, Diaz-Alonso J,Velasco G, Panina- Bordignon P. The cannabinoid receptor CB1 contributes to thedevelopment of ectopic lesions in a mouse model of endometriosis. Hum Reprod.2017 Jan;32(1):175-184. Epub 2016 Nov 7. PubMed PMID: 27821707. 14. Palomba S, Daolio J, Romeo S, Battaglia FA, Marci R, La Sala GB. Lifestyle and fertility: the influence of stress and quality of life on female fertility. Reprod Biol Endocrinol. 2018;16(1):113. Published 2018 Dec 2. doi:10.1186/s12958-018-0434-y 15. Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonataloutcomes in Jamaica: an ethnographic study. Pediatrics. 1994 Feb;93(2):254-60.PubMed PMID: 8121737 16. Smith CG, Asch RH. Acute, short-term, and chronic effects of marijuana on the female primate reproductive function. NIDA Res Monogr. 1984;44:82-96. Review.PubMed PMID: 6090911 17. Lammert S, Harrison K, Tosun N, Allen S. Menstrual Cycle in Women Who Co-useMarijuana and Tobacco. J Addict Med. 2018 May/Jun;12(3):207-211. doi:10.1097/ADM.0000000000000387. Erratum in: J Addict Med. 2018 Nov/Dec;12(6):501.PubMed PMID: 29381494; PubMed Central PMCID: PMC5970012. 18. Brents LK. Marijuana, the Endocannabinoid System and the Female Reproductive System. Yale J Biol Med. 2016;89(2):175–191. Published 2016 Jun 27. 19. Smith SK, Lenton EA, Landgren BM, Cooke ID. The short luteal phase andinfertility. Br J Obstet Gynaecol. 1984 Nov;91(11):1120-2. PubMed PMID: 6498127. 20. Walker OS, Holloway AC, Raha S. The role of the endocannabinoid system infemale reproductive tissues. J Ovarian Res. 2019 Jan 15;12(1):3. doi:10.1186/s13048-018-0478-9. Review. PubMed PMID: 30646937; PubMed Central PMCID:PMC6332911. 21. Kasman AM, Thoma ME, McLain AC, Eisenberg ML. Association between use ofmarijuana and time to pregnancy in men and women: findings from the NationalSurvey of Family Growth. Fertil Steril. 2018 May;109(5):866-871. doi:10.1016/j.fertnstert.2018.01.015. Epub 2018 Mar 16. PubMed PMID: 29555335. 22. Palomba S, Daolio J, Romeo S, Battaglia FA, Marci R, La Sala GB. Lifestyle and fertility: the influence of stress and quality of life on female fertility. Reprod Biol Endocrinol. 2018;16(1):113. Published 2018 Dec 2. doi:10.1186/s12958-018-0434-y 23. Luschnig P, Schicho R: Cannabinoids in Gynecological Diseases. Med Cannabis Cannabinoids 2019;2:14-21. doi: 10.1159/000499164 24. Neradugomma NK, Drafton K, Mor GG, Mao Q. Marijuana-derived cannabinoidsinhibit uterine endometrial stromal cell decidualization and compromisetrophoblast-endometrium cross-talk. Reprod Toxicol. 2019 Aug;87:100-107. doi:10.1016/j.reprotox.2019.05.064. Epub 2019 May 30. PubMed PMID: 31154070; PubMedCentral PMCID: PMC6613995. 25. Lojpur T, Easton Z, Raez-Villanueva S, Laviolette S, Holloway AC, Hardy DB.Δ9- Tetrahydrocannabinol leads to endoplasmic reticulum stress and mitochondrialdysfunction in human BeWo trophoblasts. Reprod Toxicol. 2019 Aug;87:21-31. doi:10.1016/j.reprotox.2019.04.008. Epub 2019 May 1. PubMed PMID: 31054322. 26. Fraser HM, Nestor JJ, Jr., Vickery BH. et al. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin. Endocrinology. 1987;121(2):612–618 27. Smith CG, Asch RH. Acute, short-term, and chronic effects of marijuana on the female primate reproductive function. NIDA Res Monogr. 1984;44:82-96. Review.PubMed PMID: 6090911. 28. Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonataloutcomes in Jamaica: an ethnographic study. Pediatrics. 1994 Feb;93(2):254-60.PubMed PMID: 8121737. 29. Coons, Kelly & Poole, Nancy. (2018). CanFASD Issue Paper: Cannabis Use During Pregnancy. 30. Koren G. Safety considerations surrounding use of treatment options for nauseaand vomiting in pregnancy. Expert Opin Drug Saf. 2017 Nov;16(11):1227-1234. doi: 10.1080/14740338.2017.1361403. Epub 2017 Aug 9. Review. PubMed PMID: 28749713. 31. Wei-Ni Lin Curry MA and PhD (2002) Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat?, Journal of Cannabis Therapeutics, 2:3-4, 63-83, DOI: 10.1300/J175v02n03_05 32. Melissa N. Slavin, Stacey Farmer & Mitch Earleywine (2016) Expectancy mediated effects of marijuana on menopause symptoms, Addiction Research & Theory, 24:4, 322- 329, DOI: 10.3109/16066359.2016.1139701 33. Ayakannu T, Taylor AH, Marczylo TH, Konje JC. New Insights of Uterine Leiomyoma Pathogenesis: Endocannabinoid System. Med Sci Monit Basic Res. 2019;25:76–87. Published 2019 Mar 7. doi:10.12659/MSMBR.914019 34. Qin H, Lin Z, Vásquez E, Xu L. The association between chronic psychologicalstress and uterine fibroids risk: A meta-analysis of observational studies.Stress Health. 2019 Aug 26. doi: 10.1002/smi.2895. [Epub ahead of print] Review. PubMed PMID: 31452302. 35. Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2018Jan;46:3-11. doi: 10.1016/j.bpobgyn.2017.09.004. Epub 2017 Oct 1. Review. PubMed PMID: 29054502 36. Walker OS, Holloway AC, Raha S. The role of the endocannabinoid system infemale reproductive tissues. J Ovarian Res. 2019 Jan 15;12(1):3. doi:10.1186/s13048-018-0478-9. Review. PubMed PMID: 30646937; PubMed Central PMCID:PMC6332911 37. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R.Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008 Jan;54(1):244-9. Epub 2007 Jul 17. PubMed PMID: 17714746; PubMed CentralPMCID: PMC2270485. 38. Zorzenon MRT, Santiago AN, Mori MA, Piovan S, Jansen CA, Perina Padilha ME,Ciotta SR, Cezar de Freitas Mathias P, Guimarães FS, Weffort de Oliveira RM,Milani PG, Mareze-Costa CE. Cannabidiol improves metabolic dysfunction inmiddle-aged diabetic rats submitted to a chronic cerebral hypoperfusion. ChemBiol Interact. 2019 Oct 1;312:108819. doi: 10.1016/j.cbi.2019.108819. Epub 2019Sep 6. PubMed PMID: 31499052. 39. Ignatowska-Jankowska B, Jankowski MM, Swiergiel AH. Cannabidiol decreases bodyweight gain in rats: involvement of CB2 receptors. Neurosci Lett. 2011 Feb18;490(1):82-4. doi: 10.1016/j.neulet.2010.12.031. Epub 2010 Dec 21. PubMed PMID:21172406. 40. Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'SullivanSE, Tan GD. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin onGlycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized,Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29. PubMed PMID:27573936. 41. Ethan Russo MD (2002) Cannabis Treatments in Obstetrics and Gynecology: A Historical Review, Journal of Cannabis Therapeutics, 2:3-4, 5-35, DOI: 10.1300/J175v02n03_02
Chapter 13 – Sex and Libido
1. Sun AJ, Eisenberg ML. Association Between Marijuana Use and Sexual Frequencyin the United States: A Population-Based Study. J Sex Med. 2017Nov;14(11):1342-1347. doi: 10.1016/j.jsxm.2017.09.005. PubMed PMID: 29110804. 2. Boo B, Kamath R, Arriaga-Gomez E, et al. Tetrahydrocannabinol Reduces Hapten-Driven Mast Cell Accumulation and Persistent Tactile Sensitivity in Mouse Model of Allergen-Provoked Localized Vulvodynia. Int J Mol Sci. 2019;20(9):2163. Published 2019 May 1. doi:10.3390/ijms20092163 3. Fuss J, Bindila L, Wiedemann K, Auer MK, Briken P, Biedermann SV. Masturbationto Orgasm Stimulates the Release of the Endocannabinoid 2-Arachidonoylglycerol inHumans. J Sex Med. 2017 Nov;14(11):1372-1379. doi: 10.1016/j.jsxm.2017.09.016.PubMed PMID: 29110806. 4. Smith AM, Ferris JA, Simpson JM, Shelley J, Pitts MK, Richters J. Cannabis useand sexual health. J Sex Med. 2010 Feb;7(2 Pt 1):787-93. doi:10.1111/j.1743-6109.2009.01453.x. Epub 2009 Aug 17. PubMed PMID: 19694929. 5. Payne KS, Mazur DJ, Hotaling JM, Pastuszak AW. Cannabis and Male Fertility: A Systematic Review. J Urol. 2019 Oct;202(4):674-681. doi:10.1097/JU.0000000000000248. Epub 2019 Sep 6. PubMed PMID: 30916627. 6. Hsiao P, Clavijo RI. Adverse Effects of Cannabis on Male Reproduction. EurUrol Focus. 2018 Apr;4(3):324-328. doi: 10.1016/j.euf.2018.08.006. Epub 2018 Aug 23. Review. PubMed PMID: 30146239.
7. Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet Gynecol. 2013 Apr;121(4):773-80. doi: 10.1097/AOG.0b013e31828786f8. PubMed PMID: 23635677.
8. Anderson L, Lewis SE, McClure N. The effects of coital lubricants on spermmotility in vitro. Hum Reprod. 1998 Dec;13(12):3351-6. PubMed PMID: 9886513. 9. Nickel JC. Medical marijuana for urologic chronic pelvic pain. Can Urol Assoc J. 2018;12(6 Suppl 3):S181–S183. doi:10.5489/cuaj.5331 10. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol. 2006;147(8):917– 925. doi:10.1038/sj.bjp.0706687 11. Optimized cannabis-based aphrodisiac and mood enhancer, https://patents.google.com/patent/US20180221333A1/en 12. Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms, https://patents.google.com/patent/US20170367875A1/en
13. Wiebe E, Just A. How Cannabis Alters Sexual Experience: A Survey of Men andWomen. J Sex Med. 2019 Nov;16(11):1758-1762. doi: 10.1016/j.jsxm.2019.07.023.Epub 2019 Aug 22. PubMed PMID: 31447385. 14. G.Scimeca et Al,Chapter 19 - Cannabis and Sexual Behavior, Handbook of Cannabis and Related Pathologies, Biology, Pharmacology, Diagnosis, and Treatment2017, Pages 180-187 15. Rajanahally S, Raheem O, Rogers M, Brisbane W, Ostrowski K, Lendvay T, WalshT. The relationship between cannabis and male infertility, sexual health, andneoplasm: a systematic review. Andrology. 2019 Mar;7(2):139-147. doi:10.1111/andr.12585. Epub 2019 Feb 15. Review. PubMed PMID: 30767424. 16. Balon, R. Cannabis and Sexuality ,Curr Sex Health Rep (2017) 9: 99. https://doi.org/10.1007/s11930-017-0112-7 17. Sex & cannabis: can it solve our intimacy problems https://mountainscholar.org/handle/10217/180253?show=full 18. Lynn BK, López JD, Miller C, Thompson J, Campian EC. The Relationship between Marijuana Use Prior to Sex and Sexual Function in Women. Sex Med. 2019Jun;7(2):192-197. doi: 10.1016/j.esxm.2019.01.003. Epub 2019 Mar 2. PubMed PMID: 30833225; PubMed Central PMCID: PMC6522945. 19. Androvicova R, Horacek J, Stark T, Drago F, Micale V. Endocannabinoid systemin sexual motivational processes: Is it a novel therapeutic horizon? PharmacolRes. 2017 Jan;115:200-208. doi: 10.1016/j.phrs.2016.11.021. Epub 2016 Nov 21.Review. PubMed PMID: 27884725. 20. Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M. Intravaginalpractices and risk of bacterial vaginosis and candidiasis infection among acohort of women in the United States. Obstet Gynecol. 2013 Apr;121(4):773-80.doi: 10.1097/AOG.0b013e31828786f8. PubMed PMID: 23635677. 21. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol. 2006;147(8):917– 925. doi:10.1038/sj.bjp.0706687 22. Klein C, Hill MN, Chang SC, Hillard CJ, Gorzalka BB. Circulatingendocannabinoid concentrations and sexual arousal in women. J Sex Med. 2012Jun;9(6):1588-601. doi: 10.1111/j.1743- 6109.2012.02708.x. Epub 2012 Mar 29.PubMed PMID: 22462722; PubMed Central PMCID: PMC3856894. 23. Hsiao P, Clavijo RI. Adverse Effects of Cannabis on Male Reproduction. EurUrol Focus. 2018 Apr;4(3):324-328. doi: 10.1016/j.euf.2018.08.006. Epub 2018 Aug 23. Review. PubMed PMID: 30146239.
Chapter 14- Gut Health
1. Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut microbiota's effect on mental health: The gut-brain axis. Clin Pract. 2017;7(4):987. Published 2017 Sep 15. doi:10.4081/cp.2017.987 2. Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE. Cannabinoids mediateopposing effects on inflammation-induced intestinal permeability. Br J Pharmacol.2012 Apr;165(8):2598-610. doi: 10.1111/j.1476-5381.2011.01589.x. PubMed PMID:21745190; PubMed Central PMCID: PMC3423254. 3. Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gutdisorders. Biochem Pharmacol. 2018 Nov;157:134-147. doi:10.1016/j.bcp.2018.07.048. Epub 2018 Aug 2. Review. PubMed PMID: 30076849. 4. Sharkey KA, Wiley JW. The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology. 2016 Aug;151(2):252-66. doi:10.1053/j.gastro.2016.04.015. Epub 2016 Apr 29. Review. PubMed PMID: 27133395;PubMed Central PMCID: PMC4961581. 5. Goyal H, Singla U, Gupta U, May E. Role of cannabis in digestive disorders.Eur J Gastroenterol Hepatol. 2017 Feb;29(2):135-143. doi:10.1097/MEG.0000000000000779. Review. PubMed PMID: 27792038. 6. Madara JL, Pappenheimer JR. Structural basis for physiological regulation ofparacellular pathways in intestinal epithelia. J Membr Biol. 1987;100(2):149-64. PubMed PMID: 3430571. 7. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases.Acta Paediatr. 2005 Apr;94(4):386-93. Review. PubMed PMID: 16092447. 8. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL (1992). Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 102: 416–423. 9. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA et al. (2004). TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol 286: G367–G376. 10. Poritz LS, Garver KI, Tilberg AF, Koltun WA (2004). Tumor necrosis factor alpha disrupts tight junction assembly. J Sur Res 116: 14–18. 11. Morehouse JL, Specian RD, Stewart JJ, Berg RD (1986). Translocation of indigenous bacteria from the gastrointestinal tract of mice after oral ricinoleic acid treatment. Gastroenterology 91: 673– 682. 12. Unno N, Fink MP (1998). Intestinal epithelial hyperpermeability. Mechanisms and relevance to disease. Gastroenterol Clin North Am 27: 289–307. 13. Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome(CFS) is accompanied by a clinical improvement: effects of age, duration ofillness and the translocation of LPS from gram-negative bacteria. NeuroEndocrinol Lett. 2008 Dec;29(6):902-10. PubMed PMID: 19112401. 14. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression:intestinal mucosal dysfunction with an increased translocation of LPS from gramnegative enterobacteria (leaky gut) plays a role in the inflammatorypathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117-24.PubMed PMID: 18283240. 15. Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE. Cannabinoids mediateopposing effects on inflammation-induced intestinal permeability. Br J Pharmacol.2012 Apr;165(8):2598-610. doi: 10.1111/j.1476-5381.2011.01589.x. PubMed PMID:21745190; PubMed Central PMCID: PMC3423254. 16. Schicho R, Storr M. IBD: Patients with IBD find symptom relief in the Cannabis field. Nat Rev Gastroenterol Hepatol. 2014;11(3):142–143. doi:10.1038/nrgastro.2013.245 17. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F,Konikoff FM. Cannabis induces a clinical response in patients with Crohn'sdisease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013Oct;11(10):1276-1280.e1. doi: 10.1016/j.cgh.2013.04.034. Epub 2013 May 4. PubMed PMID: 23648372. 18. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated withworse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis. 2014Mar;20(3):472-80. doi: 10.1097/01.MIB.0000440982.79036.d6. PubMed PMID: 24407485. 19. Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154(5):1001–1008. doi:10.1038/bjp.2008.177 20. Jamontt JM, Molleman A, Pertwee RG, Parsons ME. The effects ofDelta-tetrahydrocannabinol and cannabidiol alone and in combination on damage,inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol.2010 Jun;160(3):712-23. doi: 10.1111/j.1476- 5381.2010.00791.x. PubMed PMID:20590574; PubMed Central PMCID: PMC2931570. 21. Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L,Buchanan S, Zmeter N, Rubin DT. The Role of Cannabis in the Management ofInflammatory Bowel Disease: A Review of Clinical, Scientific, and RegulatoryInformation. Inflamm Bowel Dis. 2019 Feb 21;25(3):427-435. doi:10.1093/ibd/izy319. PubMed PMID: 30358848. 22. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current ResearchSupports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and OtherTreatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165.doi: 10.1089/can.2016.0009. eCollection 2016. Review. PubMed PMID: 28861491;PubMed Central PMCID: PMC5576607. 23. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explaintherapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowelsyndrome and other treatment- resistant conditions? Neuro Endocrinol Lett. 2008Apr;29(2):192-200. PubMed PMID: 18404144. 24. Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: canthis concept explain the therapeutic benefits of cannabis in migraine,fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2014;35(3):198-201. Review. PubMed PMID: 24977967. 25. Adejumo, Adeyinka et Al, Concomitant Cannabis Use Decreases the Risk of Alcoholic Gastritis Among Alcohol Abusers, American Journal of Gastroenterology: October 2018 - Volume 113 26. Adejumo AC, Li J, Akanbi O, Adejumo KL, Bukong TN. Reduced Prevalence ofAlcoholic Gastritis in Hospitalized Individuals Who Consume Cannabis. AlcoholClin Exp Res. 2019 Feb;43(2):270-276. doi: 10.1111/acer.13930. Epub 2018 Dec 24. PubMed PMID: 30536396. 27. Odes, H.Selwyn et al ,Human duodenal mucosal bicarbonate secretion, .,Gastroenterology, Volume 98, Issue 4, 867 – 872 28. Sexton M, Cuttler C, Finnell JS, Mischley LK. A Cross-Sectional Survey ofMedical Cannabis Users: Patterns of Use and Perceived Efficacy. CannabisCannabinoid Res. 2016 Jun 1;1(1):131-138. doi: 10.1089/can.2016.0007. eCollection2016. PubMed PMID: 28861489; PubMed Central PMCID: PMC5549439. 29. McCallum RW, Bashashati M. Cannabis for Gastroparesis: Hype or Hope? Am JGastroenterol. 2019 Jun;114(6):865-866. doi: 10.14309/ajg.0000000000000277.PubMed PMID: 31135448. 30. Jehangir A, Parkman HP. Cannabinoid Use in Patients With Gastroparesis andRelated Disorders: Prevalence and Benefit. Am J Gastroenterol. 2019Jun;114(6):945-953. doi: 10.14309/ajg.0000000000000181. PubMed PMID: 30865015. 31. Teoh D, Smith TJ, Song M, Spirtos NM. Care After Chemotherapy: PeripheralNeuropathy, Cannabis for Symptom Control, and Mindfulness. Am Soc Clin Oncol EducBook. 2018 May 23;38:469-479. doi: 10.1200/EDBK_209437. Review. PubMed PMID:30231411 32. Hazekamp A. Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis. Front Pharmacol. 2016;7:108. Published 2016 Apr 27. doi:10.3389/fphar.2016.00108 33. Richards JR. Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatmentin the Emergency Department. J Emerg Med. 2018 Mar;54(3):354-363. doi:10.1016/j.jemermed.2017.12.010. Epub 2018 Jan 5. Review. PubMed PMID: 29310960. 34. Lapoint J, Meyer S, Yu CK, et al. Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline. West J Emerg Med. 2018;19(2):380–386. doi:10.5811/westjem.2017.11.36368
Chapter 15 - Auto Immune
1. Felten R, Sagez F, Gavand P, et al, 10 most important contemporary challenges in the management of SLE, Lupus Science & Medicine 2019;6:e000303. doi: 10.1136/lupus- 2018-000303 2. Greco, Carol & Nakajima, Claire & Manzi, Susan. (2013). Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus. Current rheumatology reports. 15. 378. 10.1007/s11926-013-0378-3. 3. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009;11:e3. Published 2009 Jan 20. doi:10.1017/S1462399409000957 4. Kaplan BL, Springs AE, Kaminski NE. The profile of immune modulation bycannabidiol (CBD) involves deregulation of nuclear factor of activated T cells(NFAT). Biochem Pharmacol. 2008 Sep 15;76(6):726-37. doi:10.1016/j.bcp.2008.06.022. Epub 2008 Jul 8. PubMed PMID: 18656454; PubMed CentralPMCID: PMC2748879. 5. Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F,Marotto D, Ceribelli A, Ablin JN, Hauser W. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. 2019Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997. PubMed PMID: 31512536. 6. Wright S, Ware M, Guy G. The use of a cannabis-based medicine (Sativex) in thetreatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006Jun;45(6):781; author reply 781-2. Epub 2006 Apr 18. PubMed PMID: 16621924. 7. Lowin T, Schneider M, Pongratz G. Joints for joints: cannabinoids in thetreatment of rheumatoid arthritis. Curr Opin Rheumatol. 2019 May;31(3):271-278.doi: 10.1097/BOR.0000000000000590. PubMed PMID: 30920973. 8. D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe, Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis, Rheumatology, Volume 45, Issue 1, January 2006, Pages 50–52, 9. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, KendallDA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoidreceptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R43. doi: 10.1186/ar2401.Epub 2008 Apr 16. PubMed PMID: 18416822; PubMed Central PMCID: PMC2453762. 10. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R,Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oralanti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl AcadSci U S A. 2000 Aug 15;97(17):9561-6. PubMed PMID: 10920191; PubMed CentralPMCID: PMC16904 11. Abbott RD, Sadowski A, Alt AG. Efficacy of the Autoimmune Protocol Diet as Part of a Multi- disciplinary, Supported Lifestyle Intervention for Hashimoto's Thyroiditis. Cureus. 2019;11(4):e4556. Published 2019 Apr 27. doi:10.7759/cureus.4556 12. Konijeti GG, Kim N, Lewis JD, et al. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(11):2054–2060. doi:10.1097/MIB.0000000000001221
Chapter 16 – Skin
1. Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. Molecules. 2019;24(5):918. Published 2019 Mar 6. doi:10.3390/molecules24050918 2. Adler BL, DeLeo VA. Allergenic ingredients in commercial topical cannabinoidpreparations. J Am Acad Dermatol. 2019 Sep;81(3):847-848. doi:10.1016/j.jaad.2019.03.015. Epub 2019 Mar 15. PubMed PMID: 30885758. 3. Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. Theendocannabinoid system of the skin. A potential approach for the treatment ofskin disorders. Biochem Pharmacol. 2018 Nov;157:122-133. doi:10.1016/j.bcp.2018.08.022. Epub 2018 Aug 20. Review. PubMed PMID: 30138623. 4. Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T.Differential effectiveness of selected non-psychotropic phytocannabinoids onhuman sebocyte functions implicates their introduction in dry/seborrhoeic skinand acne treatment. Exp Dermatol. 2016 Sep;25(9):701-7. doi: 10.1111/exd.13042.Epub 2016 Jun 15. PubMed PMID: 27094344 5. Palmieri B, Laurino C, Vadalà M. A therapeutic effect of cbd-enriched ointmentin inflammatory skin diseases and cutaneous scars. Clin Ter. 2019Mar-Apr;170(2):e93-e99. doi: 10.7417/CT.2019.2116. PubMed PMID: 30993303. 6. Zouboulis CC, Jourdan E, Picardo M. Acne is an inflammatory disease andalterations of sebum composition initiate acne lesions. J Eur Acad DermatolVenereol. 2014 May;28(5):527-32. doi: 10.1111/jdv.12298. Epub 2013 Oct 18.Review. PubMed PMID: 24134468. 7. Abels C, Soeberdt M. Can we teach old drugs new tricks?-Repurposing ofneuropharmacological drugs for inflammatory skin diseases. Exp Dermatol. 2019Sep;28(9):1002-1009. doi: 10.1111/exd.13987. Epub 2019 Jul 4. PubMed PMID:31173654. 8. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, AmbrusL, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R,Bíró T. Cannabidiol exerts sebostatic and antiinflammatory effects on humansebocytes. J Clin Invest. 2014 Sep;124(9):3713-24. doi: 10.1172/JCI64628. Epub2014 Jul 25. PubMed PMID: 25061872; PubMed Central PMCID: PMC4151231. 9. Kircik LH. What's new in the management of acne vulgaris. Cutis. 2019Jul;104(1):48-52. PubMed PMID: 31487336. 10. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x 11. Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP, Ehlert KA, Wang M, vander Greef J, Rodenburg RJ, Witkamp RF. Unheated Cannabis sativa extracts and its major compound THC- acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol. 2006Apr;6(4):656-65. Epub 2005 Nov 7. PubMed PMID: 16504929. 12. Casares L, García V, Garrido-Rodríguez M, Millán E, Collado JA, García-Martín A, Peñarando J, Calzado MA, de la Vega L, Muñoz E. Cannabidiol inducesantioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2019 Sep5;28:101321. doi: 10.1016/j.redox.2019.101321. [Epub ahead of print] PubMed PMID:31518892; PubMed Central PMCID: PMC6742916. 13. Derakhshan N, Kazemi M. Cannabis for Refractory Psoriasis-High Hopes for aNovel Treatment and a Literature Review. Curr Clin Pharmacol. 2016;11(2):146-7.Review. PubMed PMID: 27164964. 14. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyteproliferation through a non-CB1/CB2 mechanism and have a potential therapeuticvalue in the treatment of psoriasis. J Dermatol Sci. 2007 Feb;45(2):87-92. Epub2006 Dec 6. PubMed PMID: 17157480. 15. Norooznezhad AH, Norooznezhad F. Cannabinoids: Possible agents for treatmentof psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses.2017 Feb;99:15-18. doi: 10.1016/j.mehy.2016.12.003. Epub 2016 Dec 14. PubMedPMID: 28110689 16. Methods and compositions of cannabis extracts, https://patents.google.com/patent/US9066910B2/en 17. Trusler AR, Clark AK, Sivamani RK, Shi VY. The Endocannabinoid System and Its Role in Eczematous Dermatoses. Dermatitis. 2017 Jan/Feb;28(1):22-32. doi:10.1097/DER.0000000000000257. Review. PubMed PMID: 28098721. 18. Assessment of the anti-inflammatory effects of cannabidiol and its fluorinated derivative in in vitro and in vivo models of atopic dermatitis, http://real.mtak.hu/83626/ 19. Gaffal E, Cron M, Glodde N, Tüting T. Anti-inflammatory activity of topicalTHC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2receptors. Allergy. 2013 Aug;68(8):994-1000. doi: 10.1111/all.12183. Epub 2013Jul 29. PubMed PMID: 23889474. 20. Maida V, Corban J. Topical Medical Cannabis: A New Treatment for WoundPain-Three Cases of Pyoderma Gangrenosum. J Pain Symptom Manage. 2017Nov;54(5):732-736. doi: 10.1016/j.jpainsymman.2017.06.005. Epub 2017 Aug 14.PubMed PMID: 28818631. 21. C Jiménez-Rodríguez, A Santana-del-Pino, J-F Jiménez-Díaz, F Hernández-Martínez, B-C Rodríguez-de-Vera, Cutaneous ulceration scattering induced topically by cannabidiol oil in the laboratory animal, European Journal of Public Health, Volume 29, Issue Supplement_1, April 2019, ckz034.017, 22. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-AceñeroMJ, Huffman JW, Jorcano JL, Guzmán M. Inhibition of skin tumor growth andangiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003 Jan;111(1):43-50. PubMed PMID: 12511587; PubMed Central PMCID: PMC151833. 23. Spigelman I. Therapeutic Targeting of Peripheral Cannabinoid Receptors in Inflammatory and Neuropathic Pain States. In: Kruger L, Light AR, editors. Translational Pain Research: From Mouse to Man. Boca Raton, FL: CRC Press/Taylor & Francis; 2010. Chapter 5.
Chapter 17 - Epilepsy
1. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breakerin neurological disease. Nat Med. 2008 Sep;14(9):923-30. doi: 10.1038/nm.f.1869. Epub 2008 Sep 5. Review. PubMed PMID: 18776886. 2. Sugaya Y, Kano M. Control of excessive neural circuit excitability andprevention of epileptic seizures by endocannabinoid signaling. Cell Mol Life Sci.2018 Aug;75(15):2793-2811. doi: 10.1007/s00018-018-2834-8. Epub 2018 May 8.Review. PubMed PMID: 29737364. 3. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ.Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity inthe hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett. 2007 Jan 3;411(1):11-6. Epub 2006 Nov 15. PubMed PMID: 17110038; PubMed Central PMCID:PMC1808496. 4. Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe M, Palkovits M,Maglóczky Z, Freund TF, Katona I. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic humanhippocampus. J Neurosci. 2008 Mar 19;28(12):2976-90. doi:10.1523/JNEUROSCI.4465-07.2008. PubMed PMID: 18354002; PubMed Central PMCID:PMC6670708. 5. Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F,Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M. Cerebrospinalfluid levels of the endocannabinoid anandamide are reduced in patients withuntreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010May;51(5):768-72. doi: 10.1111/j.1528-1167.2009.02334.x. Epub 2009 Oct 8. PubMed PMID: 19817812. 6. Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. J Epilepsy Res. 2017;7(2):61–76. Published 2017 Dec 31. doi:10.14581/jer.17012 7. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras- Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG,Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potentialtherapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia.2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review. PubMed PMID: 24854329; PubMed Central PMCID: PMC4707667. 8. Pamplona FA, da Silva LR and Coan AC (2018) Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.Front. Neurol. 9:759.doi: 10.3389/fneur.2018.00759 9. Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis forthe treatment of epilepsy in the United States. Epilepsy Behav. 2017 May;70(PtB):328-333. doi: 10.1016/j.yebeh.2016.12.032. Epub 2017 Feb 21. PubMed PMID:28254350. 10. Hausman-Kedem M, Kramer U. Efficacy of medical cannabis for treatment of refractory epilepsy in children and adolescents with emphasis on the Israeli experience. Isr Med Assoc J 2017;19:76-8) 11. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE,Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial ofCannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med.2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PubMed PMID: 28538134. 12. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014Jun;55(6):783-6. doi: 10.1111/epi.12610. Epub 2014 May 22. PubMed PMID: 24854149. 13. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction betweenclobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015Aug;56(8):1246-51. doi: 10.1111/epi.13060. Epub 2015 Jun 26. PubMed PMID:26114620. 14. Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medicalcannabis for treatment of refractory epilepsy in children and adolescents - Anobservational, longitudinal study. Brain Dev. 2018 Aug;40(7):544-551. doi:10.1016/j.braindev.2018.03.013. Epub 2018 Apr 16. PubMed PMID: 29674131. 15. Ružić Zečević D, Folić M, Tantoush Z, Radovanović M, Babić G, Janković SM.Investigational cannabinoids in seizure disorders, what have we learned thus far?Expert Opin Investig Drugs. 2018 Jun;27(6):535-541. doi:10.1080/13543784.2018.1482275. Epub 2018 Jun 6. Review. PubMed PMID: 29842819. 16. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment ofepilepsy. Epilepsy Behav. 2017 May;70(Pt B):313-318. doi:10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10. Review. PubMed PMID: 28087250. 17. Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids inanimal models of seizures, epilepsy, epileptogenesis, and epilepsy-relatedneuroprotection. Epilepsy Behav. 2017 May;70(Pt B):319-327. doi:10.1016/j.yebeh.2016.11.006. Epub 2017 Feb 9. Review. PubMed PMID: 28190698;PubMed Central PMCID: PMC5651410.